Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lale Kostakoglu

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
Ejhaem|July 18, 2022
A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYALale Kostakoglu, Federico Dalmasso, Paola Berchialla, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2015
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688Lale Kostakoglu, Fenghai Duan, Michael O Idowu, et al.
Blood|March 1, 2011
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETDavid J Straus, Jeffrey L Johnson, Ann S LaCasce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRIElizabeth R Gerstner, Zheng Zhang, James R Fink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2014
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working GroupSally F Barrington, N George Mikhaeel, Lale Kostakoglu, et al.
Haematologica|August 19, 2021
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA studyLale Kostakoglu, Federico Mattiello, Maurizio Martelli, et al.
Blood Advances|March 2, 2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYALale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 10, 2014
The Mount Sinai clinical pathway for the management of pheochromocytomaSandi-Jo Galati, Meena Said, Rebekah Gospin, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Efficacy and Safety of High-Specific-Activity <sup>131</sup>I-MIBG Therapy in Patients with Advanced Pheochromocytoma or ParagangliomaDaniel A Pryma, Bennett B Chin, Richard B Noto, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Ejhaem|July 18, 2022
A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYALale Kostakoglu, Federico Dalmasso, Paola Berchialla, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2015
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688Lale Kostakoglu, Fenghai Duan, Michael O Idowu, et al.
Blood|March 1, 2011
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETDavid J Straus, Jeffrey L Johnson, Ann S LaCasce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRIElizabeth R Gerstner, Zheng Zhang, James R Fink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2014
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working GroupSally F Barrington, N George Mikhaeel, Lale Kostakoglu, et al.
Haematologica|August 19, 2021
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA studyLale Kostakoglu, Federico Mattiello, Maurizio Martelli, et al.
Blood Advances|March 2, 2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYALale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 10, 2014
The Mount Sinai clinical pathway for the management of pheochromocytomaSandi-Jo Galati, Meena Said, Rebekah Gospin, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Efficacy and Safety of High-Specific-Activity <sup>131</sup>I-MIBG Therapy in Patients with Advanced Pheochromocytoma or ParagangliomaDaniel A Pryma, Bennett B Chin, Richard B Noto, et al.
Pageof 12